FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL)
Horwitz, S.M., Scarisbrick, J., Prince, H.M., Whittaker, S., Duvic, M., Kim, Y.H., Quaglino, P., Zinzani, P.L., Bechter, O., Eradat, H., Pinter-Brown, L., Akilov, O., Geskin, L., Sanches, J., Ortiz-RoVolume:
37
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.96_2630
Date:
June, 2019
File:
PDF, 257 KB
english, 2019